![]() ![]() The data suggests a reformulation of the AREDS formula that removes beta-carotene and adds lutein and zeaxanthin for patients at risk of AMD progression. 1 However, secondary analyses suggest the combination of lutein and zeaxanthin may be beneficial in select patient populations. The primary findings of AREDS2 indicate that neither lutein plus zeaxanthin or DHA plus EPA (omega-3 fatty acids), nor all four components combined, further reduced the risk of progression to AMD when added to the original AREDS formula. The physicians thank the efforts of our study department and patients who contributed to this landmark clinical trial.Ever since the long-awaited results of the Age-Related Eye Disease Study 2 (AREDS2) arrived in early May, optometrists have been sifting through the data to determine what-if any-changes they should make in recommending nutraceuticals to their AMD patients.Īnd, for some doctors, the initial results of the study prompt more questions than answers on matters of patient care. Multiple SCDRC patients participated in the AREDS2. The new recommended formula consists of 400 IU Vitamin E, 500 mg Vitamin C, 10 mg Lutein and 2 mg Zeaxanthin, 80 mg Zinc and 2 mg Copper.įurthermore, similar to the original AREDS findings, the AREDS2 reaffirmed that none of the modified formulations reduced the risk of progression to cataract surgery. ![]() These participants had an 18% reduction in developing advanced AMD in 5 years when compared to those who took a formulation with beta-carotene but no lutein or zeaxanthin. ![]() However, the investigators did find some benefit when they analyzed two subgroups of participants those not given beta-carotene, and those who had very little lutein and zeaxanthin in their diets. In AREDS2, there was no overall additional benefit from adding omega-3 fatty acids or a 5-to-1 mixture of lutein and zeaxanthin to the formulation. In the original AREDS, participants with AMD taking supplements were 25% less likely to progress to advanced AMD over five years as compared to those who took a placebo. Before the AREDS2 study finished, manufacturers began marketing supplements based on the study design. Prior studies had suggested that diets high in lutein, zeaxanthin, and omega-3 fatty acids protect vision. Lutein and zeaxanthin are carotenoids, a class of plant derived vitamins that includes beta-carotene both are present in leafy green vegetables and, when consumed, they accumulate in the retina. Omega-3 fatty acids are produced by plants, including algae, and are present in oily fish such as salmon. The study also examined how different combinations of the supplements performed. In 2006 the NEI launched AREDS 2, a five-year study designed to test whether the original formulation could be improved by adding omega-3 fatty acids adding lutein and zeaxanthin continuing or removing beta-carotene or reducing zinc. Also, there are concerns that high doses of zinc may cause minor side effects such as upset stomach. While many patients have benefited from the AREDS formulation, beta-carotene use has been linked to a heightened risk of lung cancer in smokers. In 2001, the Age-Related Eye Disease Study (AREDS) led by the National Eye Institute (NEI) established that daily high doses of vitamins (beta-carotene, C, E) and the mineral (zinc and copper) can slow the progression to advanced AMD. AREDS 2 UPDATE – Vitamins For Macular Degeneration ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |